Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,971 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03772288 | A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL) | withdrawn | Phase 1 | 0 | Calithera Biosciences, IncINDUSTRY | 2 | Feb 8, 2023 | clinicaltrials |
| NCT05381935 | A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors | withdrawn | Phase 1 | 0 | Elpiscience Biopharma, Ltd.INDUSTRY | 0 | Jan 31, 2023 | clinicaltrials |
| NCT05408026 | Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM | withdrawn | Phase 1 / Phase 2 | 0 | Alliance Foundation Trials, LLC.OTHER | 0 | Jan 27, 2023 | clinicaltrials |
| NCT05493618 | Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma. | withdrawn | Phase 1 / Phase 2 | 0 | Hackensack Meridian HealthOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT02389543 | Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients(SLAM) | withdrawn | Phase 1 / Phase 2 | 0 | Karyopharm Therapeutics IncINDUSTRY | 0 | Jan 26, 2023 | clinicaltrials |
| NCT05060276 | Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors | withdrawn | Phase 1 | 0 | Sorrento Therapeutics, Inc.INDUSTRY | 0 | Jan 26, 2023 | clinicaltrials |
| NCT05628545 | Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells | withdrawn | Phase 1 / Phase 2 | 0 | Guangdong GD Kongming Biotech LLCINDUSTRY | 1 | Jan 18, 2023 | clinicaltrials |
| NCT04797468 | A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor | withdrawn | Phase 1 | 0 | Shanghai Henlius BiotechINDUSTRY | 1 | Jan 17, 2023 | clinicaltrials |
| NCT05228249 | Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 13, 2023 | clinicaltrials |
| NCT00995059 | Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | Mayo ClinicOTHER | 0 | Jan 5, 2023 | clinicaltrials |
| NCT05472220 | Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma | withdrawn | Phase 1 | 0 | Pamela MunsterOTHER | 0 | Dec 27, 2022 | clinicaltrials |
| NCT04316169 | Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer | withdrawn | Phase 1 | 0 | Medical College of WisconsinOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT05168748 | CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia | withdrawn | Phase 1 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Dec 21, 2022 | clinicaltrials |
| NCT03906643 | HS-201, an HSP90 Inhibitor-linked Verteporfin for Detection of Solid Malignancies | withdrawn | Phase 1 | 0 | Herbert LyerlyOTHER | 1 | Dec 20, 2022 | clinicaltrials |
| NCT05393635 | ITIL-168 in Advanced Solid Tumors(DELTA-2) | withdrawn | Phase 1 | 0 | Instil BioINDUSTRY | 0 | Dec 20, 2022 | clinicaltrials |
| NCT01138579 | Study of the Trifunctional Antibody FBTA05 and Donor Lymphocyte Infusion in B-cell Lymphoma After Allogeneic Stem Cell Transplantation(STP-LYM-01) | withdrawn | Phase 1 / Phase 2 | 0 | Technical University of MunichOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT05570188 | Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Kunming Hope of Health HospitalOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05571540 | Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL | withdrawn | Phase 1 / Phase 2 | 0 | Kunming Hope of Health HospitalOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05572463 | A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 7 | Nov 18, 2022 | clinicaltrials |
| NCT05093387 | SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer | withdrawn | Phase 1 | 0 | Northwestern UniversityOTHER | 1 | Nov 15, 2022 | clinicaltrials |
| NCT04639843 | Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Nov 4, 2022 | clinicaltrials |
| NCT05246384 | Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Rhizen Pharmaceuticals SAINDUSTRY | 0 | Oct 31, 2022 | clinicaltrials |
| NCT05433402 | Repurposing the Antipsychotic Drug Chlorpromazine as Adjuvant Therapeutic Agent for Resected Stage III Colon Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Sadat City UniversityOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT03612466 | A Dose Finding Study of CycloSam® Combined With External Beam Radiotherapy | withdrawn | Phase 1 | 0 | Albert Einstein College of MedicineOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT03649464 | Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants | withdrawn | Phase 1 / Phase 2 | 0 | Oblato, Inc.INDUSTRY | 0 | Oct 7, 2022 | clinicaltrials |
| NCT03709550 | Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT00560495 | Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT04635683 | Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma | withdrawn | Phase 1 | 0 | Yazeed SawalhaOTHER | 0 | Sep 30, 2022 | clinicaltrials |
| NCT05469490 | Safety of Navoximod and NLG802 With Stereotactic Body Radiotherapy (SBRT) Treatment of Advanced Solid Tumors | withdrawn | Phase 1 | 0 | Luke, Jason, MDOTHER | 0 | Sep 30, 2022 | clinicaltrials |
| NCT04998747 | A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)(ProxiMMity-1) | withdrawn | Phase 1 | 0 | AmgenINDUSTRY | 0 | Sep 27, 2022 | clinicaltrials |
| NCT05262842 | JS001+IMP4297 in Patients With Advanced Cancer | withdrawn | Phase 1 | 0 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 0 | Sep 21, 2022 | clinicaltrials |
| NCT03209869 | Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2 | withdrawn | Phase 1 | 0 | University of Wisconsin, MadisonOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT04878484 | Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors | withdrawn | Phase 1 | 0 | Athenex, Inc.INDUSTRY | 0 | Sep 2, 2022 | clinicaltrials |
| NCT04200066 | A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma | withdrawn | Phase 1 | 0 | University of RochesterOTHER | 0 | Aug 22, 2022 | clinicaltrials |
| NCT04972253 | Phase I BLASST-3 Trial((BLASST)-3) | withdrawn | Phase 1 | 0 | Guru P. SonpavdeOTHER | 0 | Aug 10, 2022 | clinicaltrials |
| NCT05191017 | Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC | withdrawn | Phase 1 / Phase 2 | 0 | Nuvation Bio Inc.INDUSTRY | 1 | Aug 5, 2022 | clinicaltrials |
| NCT02117817 | Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer | withdrawn | Phase 1 | 0 | Rutgers, The State University of New JerseyOTHER | 0 | Jul 28, 2022 | clinicaltrials |
| NCT04371458 | Thymectomy With and Without Povidone-iodine Pleural Lavage in Stage IVA Thymic Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Yale UniversityOTHER | 0 | Jul 25, 2022 | clinicaltrials |
| NCT03768310 | CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA) | withdrawn | Phase 1 | 0 | Baylor College of MedicineOTHER | 1 | Jul 21, 2022 | clinicaltrials |
| NCT02569489 | Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer | withdrawn | Phase 1 | 0 | HUYABIO International, LLC.INDUSTRY | 0 | Jul 18, 2022 | clinicaltrials |
| NCT04315246 | 177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma) | withdrawn | Phase 1 / Phase 2 | 0 | Y-mAbs TherapeuticsINDUSTRY | 2 | Jul 15, 2022 | clinicaltrials |
| NCT04354727 | A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy | withdrawn | Phase 1 / Phase 2 | 0 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT03427320 | Imaging of Advanced Tumours Using [131]I-IAZA | withdrawn | Phase 1 / Phase 2 | 0 | University of AlbertaOTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT02562612 | Study of SM-88 in Advanced Cancers | withdrawn | Phase 1 / Phase 2 | 0 | Tyme, IncINDUSTRY | 0 | Jul 1, 2022 | clinicaltrials |
| NCT04512261 | TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases(TOPAZ) | withdrawn | Phase 1 / Phase 2 | 0 | Reva BashoOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT03634683 | A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation | withdrawn | Phase 1 / Phase 2 | 0 | Lion TCR Pte. Ltd.INDUSTRY | 2 | Jun 30, 2022 | clinicaltrials |
| NCT02035085 | 19F Hot Spot MRI of Human Adipose-derived Stem Cells for Breast Reconstruction(CS-1000) | withdrawn | Phase 1 | 0 | Johns Hopkins UniversityOTHER | 1 | Jun 27, 2022 | clinicaltrials |
| NCT04941378 | OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian Cancer | withdrawn | Phase 1 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 27, 2022 | clinicaltrials |
| NCT05279859 | A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies(HERKULES-4) | withdrawn | Phase 1 / Phase 2 | 0 | Erasca, Inc.INDUSTRY | 1 | Jun 15, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Feb 8, 2023source: clinicaltrials